cross sectional imaging in pancreatic cancer · 2015-05-15 · background • 3% cancers in uk •...

33
Cross Sectional Imaging in Pancreatic Cancer Raneem Albazaz MBChB (Hons) BSc (Hons) MRCS FRCR Consultant GI Radiologist Leeds Teaching Hospitals NHS Trust

Upload: others

Post on 04-Apr-2020

1 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Cross Sectional Imaging in Pancreatic Cancer

Raneem Albazaz MBChB (Hons) BSc (Hons) MRCS FRCR

Consultant GI Radiologist

Leeds Teaching Hospitals NHS Trust

Page 2: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Background

• 3% cancers in UK

• Ductal adenocarcinoma commonest

• Predilection for head and neck

• Obstructive jaundice

• Surgery primary treatment

• 5 year survival following resection only 10%

• NETs and cystic tumours less common but better prognosis

Vincent et al, Lancet 2011;378:607-620

Page 3: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

How is Suspected Pancreatic Cancer Investigated?

• Tumour markers

• Ultrasound

• Computed tomography (CT)

• Magnetic resonance imaging (MRI incl. MRCP)

• Endoscopic ultrasound (EUS)

• Endoscopic retrograde cholangiopancreatography (ERCP)

• Positron emission tomography (PET-CT)

• Other nuclear medicine eg. octreotide scan, nanocolloid

Page 4: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

How is Suspected Pancreatic Cancer Investigated?

• Tumour markers

• Ultrasound

• Computed tomography (CT)

• Magnetic resonance imaging (MRI incl. MRCP)

• Endoscopic ultrasound (EUS)

• Endoscopic retrograde cholangiopancreatography (ERCP)

• Positron emission tomography (PET-CT)

• Other nuclear medicine eg. octreotide scan, nanocolloid

Page 5: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

What is the Role of Imaging?

• Preoperative • Is it cancer?

• Localise tumour

• Is it resectable? • Local extent • Distant disease

• Anatomic variants • Vascular/biliary tree

• Post-operative • Identify complications • Recurrence

Page 6: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

What is the Role of Imaging?

• Palliative

• Size of tumour if chemorad considered (<5cm)

• Response to palliative treatment

Page 7: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

CT vs MRI

• If we know it’s cancer then it doesn’t matter which!

• Similar capability to assess local tumour extent

• NB. both can underestimate disease

Takakura et al. Abdom Imaging 2011;36:457-62

Motosugi et al, Radiology 2011;260:446-453

Verbeke et al, Pancreatology 2010;10:300

Page 8: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Spatial Resolution (Clarity)

• CT better than MRI • Wide anatomical coverage • Comprehensive local and distant disease assessment • Rapid

• Eliminates artefact • Multi-planar reconstruction

Page 9: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive
Page 10: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Contrast Resolution (Intensity)

• MRI better than CT • MRI parameters can be altered to improve resolution

• Better for lesion characterisation/detection

• Long examination time

Page 11: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Liver lesion characterisation in pancreatic cancer ? Metastasis

Page 12: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

MRI

• Indications • Equivocal CT findings • Characterising lesions (primary tumour, liver lesion) • Defining anatomy of biliary tree and PD • Patient factors

• Renal impairment precluding CECT • Iodine contrast allergy

• Contraindications • Pacemaker • Aneurysm clips • Metal FB eye • Claustrophobia • Inability to breath hold

Page 13: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

56 year old male Abdominal pain, drinks half litre vodka per day

art

Page 14: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

56 year old male Drinks half litre vodka per day

T2 T1 T1 art

T1 delayed DWI ADC

Page 15: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Staging CT

• Contrast

• Timing crucial

• Pancreas protocol

• Triple phase CAP

• Non contrast (calcification)

• Late arterial phase 35 sec (pancreatic phase = primary tumour & vessels)

• Portal venous phase 70 sec (metastases)

Page 16: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

86 year old female #NOF, acutely deranged LFTS

art pv non con

Page 17: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Pancreatic Cancer Diagnosis

• Pancreatic adenocarcinoma • Hypovascular

• Compared to adjacent enhancing pancreas

• 10% isoattenuating • Secondary signs helpful • Double duct sign • Atrophic distal pancreas • Interrupted duct • Vascular occlusion

• Biliary stents / pancreatitis can be problematic

Page 18: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

62year old male Early satiety and epigastric pain, normal OGD, borderline abnormal LFTs

pv

pv

Page 19: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

54 year old female 6 week history central abdo pain radiating to back, dilated PD on US

non con

pv

art

MIP

Page 20: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

EUS

• Indeterminate findings on CT/MRI

• FNA possible

• Cytological assessment

• Operator dependent

• Limited availability

Page 21: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Pancreatic Cancer Staging

• T staging (90% focal mass) • TX

• Primary tumor cannot be assessed • T0

• No evidence of primary tumor • Tis

• Carcinoma in situ • T1

• ≤ 2 cm in diameter and confined to the pancreas • T2

• > 2 cm in diameter and confined to the pancreas • T3

• Extension beyond pancreas but not involving coeliac axis or SMA • T4

• Involvement of coeliac axis, SMA, stomach, bowel (unresectable) • Lymphatic channels along coeliac axis or SMV

Page 22: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Pancreatic Cancer Staging

• N staging • NX

• Regional lymph nodes not assessed

• N0 • No involvement of regional lymph nodes

• N1 • Involvement of regional lymph nodes

• Prognosis directly related to nodal involvement

• CT not accurate for nodal involvement

Roche et al, AJR 2003; 180:475–480

Geer et al, Am J Surg 1993; 165:68–73

Page 23: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Pancreatic Cancer Staging

• CT limited in detection of small liver and peritoneal metastases

• Lung metastases not usually found if no other contraindication to surgery

Nordback et al, Scand J Gastroenterol 2004;39:81–86

Page 24: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Vascular Resectability

• Venous invasion • PV • Splenic vein • SMV

• Gastrocolic trunk • First jejunal branch

• Arterial invasion • Coeliac trunk • Hepatic artery • SMA

Page 25: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Vascular Invasion

• Loss of fat plane between tumour and vessel

• Flattening / slight irregularity of one side (ie. <180°) • Questionable involvement

• Tumour extending around at least two sides (ie. 180°) • Definite involvement, en bloc venous resection may still be

possible

• Circumferential narrowing or occlusion • Mostly unresectable • Short-segment focal venous occlusion may allow local resection

Page 26: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

72 year old male Abdo pain, hypotension, PR bleeding

pv

pv

pv

pv

Page 27: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

72 year old male Abdo pain, hypotension, PR bleeding

Page 28: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

72 year old male Abdo pain, hypotension, PR bleeding

T2 T1 + gad DWI ADC

Page 29: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

65 year old female Abdominal pain and distension, ascites on US

pv

pv

Page 30: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

58 year old female Upper abdo pain, dilated CBD on US

art

pv

Page 31: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

72 year old male Abdo and back pain with weight loss, normal OGD

art

art

pv

pv

Page 32: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Follow-up

• No role for routine imaging post surgery

• Only if symptomatic

• Only if recurrence suspected clinically

• Assess response to chemotherapy in palliative cases

Page 33: Cross Sectional Imaging in Pancreatic Cancer · 2015-05-15 · Background • 3% cancers in UK • Ductal adenocarcinoma commonest • Predilection for head and neck • Obstructive

Take Home Points

• CT usually provides required information (pancreatic CT for staging)

• Other tests available for problem solving

• Consider suitability of test in clinical context